About Us-Guangzhou Raytec Biotechnology Co., Ltd

about us

About Us

Founded in September 2014, Guangzhou Ruitai Biotechnology is a high-tech enterprise that specializes in the research, development, production, and sales of ophthalmic and regenerative medical materials. It has received numerous honors such as "Deloitte China's Rising Star," "Most Capital Market Attention Award," and "Guangdong Province Specialized, Sophisticated, Innovative, and Unique Small and Medium-sized Enterprise." The company currently has nearly 100 employees, 80% of whom hold bachelor's degrees or higher, and all have over five years of industry experience. Its research and development products cover ophthalmic surface, glaucoma, ametropia, orthopedic regenerative materials, and other directions, with 52 authorized patents (including 35 invention patents and 17 utility model patents), and multiple products' technological levels have reached domestic leading and world-class standards.

The company's product research and development transformation center has achieved research and development layouts covering regenerative medical materials, corneal diseases, contact lenses, and other fields. Among them, it has established a "Regenerative Medical Materials Science and Technology Cooperation Base" with the National Biomedical Materials Engineering Technology Research Center of Sichuan University to promote the transformation of regenerative medical materials; jointly established the "Shandong Provincial Engineering Research Center for Corneal Diseases" with Shandong Provincial Eye Hospital to accelerate clinical research on corneal disease treatment; in addition, the company has also established an "Overseas Joint Development Laboratory for Contact Lenses" in Brisbane, Australia, with the globally renowned contact lens research and development organization CAPRICORNIA CONTACT LENS PTY LTD, focusing on the development of contact lenses.

In April 2020, the company independently developed the first active wet state biological amniotic membrane "Ruixiu Fu®" in China Officially launched, it was rated as a "Guangdong Province Famous High tech Product (the first domestic product that can replace imported products)" that year. This product uses a safe and efficient processing technology combined with an exclusively developed amniotic membrane preservation solution to create a biological amniotic membrane with activity similar to fresh amniotic membrane and superior product characteristics to fresh amniotic membrane, with a shelf life of up to 3 years. At present, 26 provinces have completed network deployment, achieving full coverage of 500 tertiary hospitals in China, as well as listed ophthalmic hospitals such as Aier, Huaxia, and He's.

On June 20, 2023, the first scleral mirror in China named"Epicon A®" originally imported by Raytec Biological was approved for market. this product is synchronized with the company's launch of the world's only approved scleral lens care device, "Epjing TM", which forms a complete service cycle solution from scleral lens fitting, cleaning to disinfection.

By the end of 2026, Ruitai Biotechnology will establish the largest industrial research and production base for ophthalmic and orthopedic regenerative medicine in China, with a total investment of hundreds of millions of yuan and an area of 30000 square meters, in Wenjiang Medical City. The research and transformation will cover three major sectors: ocular surface, optometry and glaucoma. Building the largest and most distinctive renewable medical materials industry base in China will undoubtedly benefit thousands of households.

500

Coverage

Provincial network hanging

Authorized Patent

30000

㎡

Floor Area

CULTURE

Corporate culture

Join hands in innovation, share responsibilities, and embrace multiculturalism

I. Core Philosophy: Constant Innovation

Innovation is the core driving force for sustained enterprise development. We firmly believe that only through continuous innovation can we maintain a leading position in the fierce market competition. We encourage employees to challenge traditions, to be brave in trying new things, and to explore unknown areas with an open mindset.

To cultivate a sense of innovation, we provide rich training and learning resources to help employees continuously improve their professional skills and innovative thinking. At the same time, we have established a flexible work mechanism to encourage cross-departmental cooperation, sharing of knowledge and experience, and thereby sparking more innovation.

II. Social Responsibility: Shared Burden

As a socially responsible enterprise, we deeply understand that our mission lies not only in making profits, but also in making contributions to society. We actively fulfill our social responsibilities, pay attention to environmental protection, and are committed to achieving sustainable development.

We advocate that employees pay attention to social issues, participate in public welfare activities, and contribute to social progress together. At the same time, we have established close cooperative relationships with our partners to jointly promote the healthy development of the industry chain and achieve mutual benefits.

III. Multiculturalism: Inclusion and Mutual Learning

We believe that multiculturalism is an important support for enterprise development. We respect and appreciate employees from different backgrounds, encouraging them to learn from and inspire each other in their work.

To cultivate an inclusive cultural atmosphere, we regularly organize cultural exchange and team-building activities to enhance mutual understanding and friendship among employees. We advocate an open and inclusive mindset, encouraging employees to bridge cultural differences and jointly create a better future.

Mission

Leading a Better Life with Technological Innovation

Vision

Becoming the most trustworthy ophthalmic medical enterprise

Values

Constant Innovation、 Shared Burden、Inclusion and Mutual Learning

Team introduce

Team Introduction

The company has established a research and development team led by Dr. Lin Yongliang, a scientific expert from Guangzhou, with 13 members (including 3 Ph.D. holders and 4 master's degree holders). The team has more than 60 research and development projects, resulting in over 50 patents and more than 10 certified product conversions. Members of the team have successively participated in and undertaken various major science and technology projects, such as the National Key R&D Program, the National Natural Science Foundation of China, the Guangdong Provincial Science and Technology Plan, and the Sichuan Provincial Science and Technology Plan,and have solid experience in basic research.

In addition, the company boasts a leading sales team in China, specializing in ophthalmology and characterized by academic promotion, centered around its Co-founder and General Manager, Mr. Xu Hao. With over 5 years of sales experience, the team possesses national ophthalmology KOL resources as well as high-quality and extensive client resources.

DEVELOPMENT HISTORYh

Development history

2023

In January, it was awarded the honor of being a specialized, innovative, and medium-sized enterprise;

In February, it successfully completed nearly 100 million yuan in A+ round of financing;

In June, the first scleral lens in China, "Epicon A®", was approved for market launch through original introduction. Simultaneously, the company launched the "Epjing TM", the world's only scleral lens-specific care device approved by the US FDA, forming a comprehensive solution for scleral lens fitting, cleaning, and sterilization;

In July, Epicon (Chengdu) Medical Technology Co., Ltd., a joint venture between Guangzhou Raytec Biotechnology Co., Ltd. and CAPRICORNIA CONTACT LENS PTY LTD, a well-known Australian contact lens research and development institution, was officially established in Wenjiang, Chengdu.

2014

Guangzhou Raytec Biotechnology Co., Ltd. was established in Guangzhou

2015

In July, wet amniotic membrane products - Rui Xiufu^® Project officially launched

2020

In April, the exclusively developed ophthalmic wet amniotic membrane was launched for sale;

In May, "scleral lens" (Epicon) was included in the Hainan Bo'ao Real-World Evidence pilot program;

In December, the company was recognized as a high-tech enterprise.

2021

In January, the company established its own ophthalmic sales and marketing team, gaining control of multiple channel sales and market resources;

In March, the ophthalmic business division launched three main business areas side by side:

√ Eye surface repair

√ Minimally invasive glaucoma surgery (MIGS)

√ Correction of refractive errors

In December, the wet amniotic membrane product, Ruixiufu^@, achieved sales revenue of tens of millions of yuan.

2022

Completed tens of millions of A-round financing.

2023

2014

2015

2020

2021

2022

HONORA PTIFICATE

Qualifications & Honor

Famous high-tech products in 2020

Biological amniotic membrane for ophthalmology

High Technology Expertise

Raytecbio

Specialized, refined, and innovative small and medium-sized enterprises in Guangdong Province

High-tech products in guangdong province

Techniques for preparation and preservation of biological materials

Guangdong Province abide by the contract and credit enterprises

The 10th China Innovation and Entrepreneurship Competition (Guangdong Guangzhou Division) and the 6th Yangcheng "Science and Technology Innovation Cup" Innovation and Entrepreneurship Competition in 2021

Biomedical Industry Growth Group - Winner

Certified by ISO13485:2016 Quality Management System

Corneal Disease Engineering Research Center established in collaboration with Shandong Provincial Ophthalmology Hospital

"Brilliant Star" enterprise in the second "Brilliant Heat List" medical track

Shortlisted for the Top 50 Biotechnology Innovation Enterprises in the 6th Guangdong Hong Kong Macao Greater Bay Area

Leading enterprise in Guangzhou's planned listing for 2023

National technology-based small and medium-sized enterprises

Approved by medical ethics

Certified by GMP production workshop

Innovative small and medium-sized enterprises

Registration and warehousing of biopharmaceutical enterprises (institutions)

2021 Deloitte Guangzhou Tomorrow Star Enterprise